Idiosyncratic drug-induced liver injury: An update on the 2007 overview

Expert Opinion on Drug Safety

Volumn 13, Issue 1, 2014, Pages 67-81

  Hussaini, S Hyder ^a   Farrington, Elizabeth Anne ^a  

^a ROYAL CORNWALL HOSPITAL   (United Kingdom)

Author keywords

Acute liver failure; Candidate gene association study; Drug induced hepatoxicity; Drug induced liver injury; Genome wide association study; Non Alcohol related fatty liver disease; Roussel Uclaf causality assessment method

Indexed keywords

ABACAVIR; AMINOTRANSFERASE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; CYTOCHROME P450; CYTOKINE; DICLOFENAC; DRUG METABOLIZING ENZYME; FLUCLOXACILLIN; GLUTATHIONE TRANSFERASE; HALOTHANE; HERBACEOUS AGENT; HLA ANTIGEN; LUMIRACOXIB; MINOCYCLINE; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; PERHEXILINE; PHENYTOIN; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG; VALPROIC ACID; XIMELAGATRAN;

ACUTE LIVER FAILURE; AGE; ALLERGIC REACTION; AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; DOSE RESPONSE; DRUG INDUCED AUTOIMMUNE HEPATITIS; DRUG INDUCED DISEASE; GENDER; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HEPATITIS E; HUMAN; IDIOSYNCRATIC DRUG INDUCED LIVER INJURY; IMMUNE MEDIATED INJURY; INCIDENCE; LIVER BIOPSY; LIVER CELL; LIVER FUNCTION TEST; LIVER TOXICITY; MORBIDITY; MORTALITY; PATHOGENESIS; PHENOTYPE; PROGNOSIS; RARE DISEASE; REVIEW; RISK FACTOR; SIDE EFFECT; TOXIC HEPATITIS; WESTERN HEMISPHERE;

ANIMALS; BIOLOGICAL MARKERS; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HLA ANTIGENS; HUMANS; INCIDENCE; MALE; PHENOTYPE; REGISTRIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84890499263     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.828032     Document Type: Review

References (143)

1. Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 2006;43:618-31
2. Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis 2009;29:337-47
3. Bjornsson E. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther 2010;32:3-13
4. Russo MW, Galanko JA, Shrestha R, et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004;10:1018-23 (Pubitemid 39232756)
5. Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010;52:730-42
6. Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opinion on Drug Safety 2007;6(6):673-84 (Pubitemid 351308279)
7. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002;36:451-5 (Pubitemid 34810366)
8. Fontana RJ. Acute liver failure due to drugs. Semin Liver Dis 2008;28:175-87 (Pubitemid 351632957)
9. Bjornsson ES, Bergmann OM, Bjornsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of iceland. Gastroenterology 2013;144:1419-25
10. Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011;89:806-15
11. Hussaini SH, OBrien CS, Despott EJ, et al. Antibiotic therapy: a major cause of drug-induced jaundice in southwest England. Eur J Gastroenterol Hepatol 2007;19:15-20 (Pubitemid 46066863)
12. De Valle MB, Klinteberg V, Alem N, et al. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther 2006;24:1187-95 (Pubitemid 44427506)
13. Li AP. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the Multiple Determinant Hypothesis for the manifestation of idiosyncratic drug toxicity. Chem Biol Interact 2002;142:7-23 (Pubitemid 35232550)
14. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005;4:489-99 (Pubitemid 40861991)
15. Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009;16:3041-53
16. Verma S, Kaplowitz N. Diagnosis, management and prevention of drug-induced liver injury. Gut 2009;58:1555-64
17. Russmann S, Jetter A, Kullak-Ublick GA. Pharmacogenetics of drug-induced liver injury. Hepatology 2010;52:748-61
18. Lammert C, Bjornsson E, Niklasson A, et al. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010;51:615-20
19. Ashrafian H, Horowitz JD, Frenneaux MP. Perhexiline. Cardiovasc Drug Rev 2007;25:76-97
20. Pachkoria K, Lucena MI, Ruiz-Cabello F, et al. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). Br J Pharmacol 2007;150:808-81
21. Aithal GP, Day CP, Leathart JB, et al. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 2000;10:511-18
22. Daly AK, Aithal GP, Leathart JB, et al. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007;132:272-81 (Pubitemid 46108755)
23. Vuilleumier N, Rossier MF, Chiappe A, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 2006;62:423-9 (Pubitemid 44069498)
24. Sun F, Chen Y, Xiang Y, et al. Drug-metabolising enzyme polymorphisms and predisposition to anti-Tuberculosis drug-induced liver injury: a meta-Analysis. Int J Tuberc Lung Dis 2008;12:994-1002
25. Huang YS, Chern HD, Su WJ, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003;37:924-30
26. Kukongviriyapan V, Prawan A, Tassaneyakul W, et al. N-Acetyltransferase-2 genotypes in the Thai population. Br J Clin Pharmacol 2003;55:278-81
27. Huang YS, Su WJ, Huang YH, et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-Transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 2007;47:128-34
28. Daly AK, Aithal GP, Leathart JB, et al. Genetic susceptibility to diclofenac-induced hepatotoxicity contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007;132:272-81 (Pubitemid 46108755)
29. Lucena MI, Andrade RJ, Martinez C, et al. Glutathione S-Transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 2008;48:588-96
30. Huang YS. Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury. Expert Opin Drug Metab Toxicol 2007;3:1-8
31. Leiro V, Fernandez-Villar A, Valverde D, et al. Influence of glutathione S-Transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int 2008;28:835-9 (Pubitemid 351818646)
32. Uetrecht J. Idiosyncratic drug reactions: past, present, and future. Chem Res Toxicol 2008;21:84-92 (Pubitemid 351219710)
33. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B 5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-Transcriptase inhibitor abacavir. Lancet 2002;359:727-32 (Pubitemid 34215071)
34. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002;359:1121-2 (Pubitemid 34270738)
35. Chessman D, Kostenko L, Lethborg T, et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008;28:822-32 (Pubitemid 351784513)
36. Mallal S, Phillips E, Carosi G, et al. HLA-B 5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-7
37. Hautekeete ML, Horsmans Y, van Waeyenberge C, et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 1999;117:1181-6 (Pubitemid 29512678)
38. ODonohue J, Oien KA, Donaldson P, et al. Co-Amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000;47:717-20
39. Donaldson PT, Daly AK, Henderson J, et al. Human leucocyte antigen class II genotype in susceptibility and resistance to coamoxiclav-induced liver injury. J Hepatol 2010;53:1049-53
40. Lucena MI, Molokhia M, Shen Y, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011;141:338-47
41. Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B 5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009;41:816-19
42. Russmann S, Kaye JA, Jick SS, et al. H. Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database. Br J Clin Pharmacol 2005;60:76-82 (Pubitemid 40942784)
43. Kindmark A, Jawaid A, Harbron CG, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008;8:186-95 (Pubitemid 351712643)
44. Singer JB, Lewitzky S, Leroy E, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010;42:711-14
45. Pachkoria K, Lucena MI, Crespo E, et al. Analysis of IL-10, IL-4 and TNF-Alpha polymorphisms in drug-induced liver injury (DILI) and its outcome. J Hepatol 2008;49:107-14
46. Stieger B, Meier Y, Meier PJ. The bile salt export pump. Pflugers Arch 2007;453:611-20 (Pubitemid 46192534)
47. Lang C, Meier Y, Stieger B, et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics 2007;17:47-60 (Pubitemid 46183791)
48. Meier Y, Zodan T, Lang C, et al. Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331TC polymorphism in the bile salt export pump. World J Gastroenterol 2008;14:38-4
49. Dalton HR, Fellows HJ, Stableforth W, et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther 2007;26:1429-35 (Pubitemid 350045603)
50. Bjornsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010;51:2040-8
51. Hoofnagle JH. Drug-induced liver network (DILIN). Hepatology 2004;40:773
52. Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: long-Term follow-up in a hepatotoxicity registry. Hepatology 2006;44:1581-8 (Pubitemid 44953663)
53. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: The reactive metabolite syndromes. Lancet 2000;356:1587-91
54. Pessayre D, Berson A, Fromenty B, et al. Mitochondria in steatohepatitis. Semin Liver Dis 2001;21:57-69 (Pubitemid 32240486)
55. Beninchou C, Danan G, Benhamou JP, et al. Criteria of drug-induced liver disorders. Report of an International Consensus Meeting. J Hepatol 1990;11:272-6
56. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005;42:481-9 (Pubitemid 41061102)
57. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug induced liver injury in the United States. Gastroenterology 2008;135:1924-34
58. Emerson SU, Purcell RH. Hepatitis E virus. Rev Med Virol 2003;13:145-54 (Pubitemid 36566084)
59. Levine DF, Bendall RP, Teo CG. Hepatitis E acquired in the UK. Gut 2000;47:740
60. Ijaz S, Arnold E, Banks M, et al. Non-Travel-Associated hepatitis E in England and Wales: demographic, clinical, and molecular epidemiological characteristics. J Infect Dis 2005;192:1166-72 (Pubitemid 41368415)
61. Mansuy JM, Peron JM, Abravanel F, et al. Hepatitis E in the south west of France in individuals who have never visited an endemic area. J Med Virol 2004;74:419-24 (Pubitemid 39281640)
62. Dalton HR, Fellows HJ, Gane EJ, et al. Hepatitis E in New Zealand. J Gastroenterol Hepatol 2007;22:1236-40 (Pubitemid 47222654)
63. Yazaki Y, Mizuo H, Takahashi M, et al. Sporadic acute or fulminant hepatitis E in Hokkaido, Japan, may be food-borne, as suggested by the presence of hepatitis E virus in pig liver as food. J Gen Virol 2003;84:2351-7 (Pubitemid 37063123)
64. Dalton HR, Thurairajah PH, Fellows HJ, et al. Autochthonous hepatitis E in southwest England. J Viral Hepat 2007;14:304-9 (Pubitemid 46587850)
65. Davern TJ, Chalasani N, Fontana RJ, et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology 2011;141:1665-72
66. Kamar N, Selves J, Mansuy J-M, et al. Hepatitis E virus and chronic hepatitis in organ-Transplant recipients. N Engl J Med 2008;358:811-17 (Pubitemid 351281642)
67. Kuniholm MH, Purcell RH, McQuillan GM, et al. Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988-1994. J Infect Dis 2009;200:48-56
68. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002;6:755-74
69. Vierling JM. The pathogenesis of autoimmune hepatitis. Hirschfield GM, Heathcote EJ, editors. In: Autoimmune hepatitis. Springer, New York; 2012. p. 3-49
70. Goldstein NS, Bayati N, Silverman AL, et al. Minocycline as a cause of drug-induced autoimmune hepatitis: report of four cases and comparison with autoimmune hepatitis. Am J Clin Pathol 2000;114:591-8
71. Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 2011;54:931-9
72. Stricker BH, Blok AP, Claas FH, et al. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology 1988;8:599-606
73. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-30 (Pubitemid 23333873)
74. Lucena MI, Camargo R, Andrade RJ, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001;33:123-30 (Pubitemid 32016894)
75. Rochon J, Protiva P, Seeff LB, et al. Reliability of the Roussel Uclaf Causality assessment method for assessing causality in drug-induced liver injury. Hepatology 2008;48:1175-83
76. Takikawa H, Takamori Y, Kumagi T, et al. Assessment of 387 Japanese cases of drug induced liver injury by the diagnostic scale of the international consensus meeting. Hepatol Res 2003;27:192-5 (Pubitemid 37407666)
77. Takikawa H, Murata Y, Horiike N, et al. Drug-induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006. Hepatol Res 2009;39:427-31
78. Fontana RJ, Watkins PB, Bonkovsky HL, et al. Rationale, design and conduct of the Drug Induced Liver Injury Network prospective study. Drug Saf 2009;32:55-68
79. Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010;51:2117-26
80. Kleiner DE. The pathology of drug-induced liver disease. Semin Liver Dis 2009;29:364-72
81. Bjornsson E. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther 2010;32:3-13
82. Bjornsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther 2007;25:1411-12
83. Zimmerman HJ. Drug-induced liver disease (Chapter 16). Zimmerman, editor. In: Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver. 2nd edition. Lippincott, Williams and Wilkins; Philadelphia, PA: 1999. p. 427-56
84. OGrady JG, Alexander GJ, Hayllar KM, et al. Early indicators in the prognosis of fulminant hepatic failure. Gastroenterology 1989;97:439-45 (Pubitemid 19192181)
85. Gulmez S E, Moore N, Pageaux G, et al. Causality of drugs involved in acute liver failure leading to transplantation: results from the study of acute liver transplant (SALT). Drug Saff 2013;32:1-8
86. Bjornsson E, Davidsdottir L. The long-Term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol 2009;50:511-17
87. Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut 1999;44:731-5 (Pubitemid 29195925)
88. Larry D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002;22:145-55
89. Fountain FF, Tolley E, Chrisman CR, et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005;128:116-23 (Pubitemid 40994462)
90. Maddrey WC. Drug-induced hepatotoxicity: 2005. J Clin Gastroenterol 2005;39:S83-9
91. Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization: The influence of age and gender. Hepatology 2009;49:2001-9
92. Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly. Best Pract Res Clin gastroenterol 2001;15:897-918 (Pubitemid 34110600)
93. Meier Y, Cavallaro M, Roos M, et al. Incidence of drug induced liver injury in medical patients. Eur J Clin Pharmacol 2005;61:135-43 (Pubitemid 40674746)
94. De Abajo FJ, Montero D, Madurga M, et al. Acute and clinically relevant drug -induced liver injury: a population based case-control study. Br J Pharmacol 2004;58:71-80 (Pubitemid 38901470)
95. Lammert C, Einarsson S, Saha C, et al. Relationship between daily dose of oral medications and idiosyncratic drug induced liver injury: search for signals. Hepatology 2008;47:2003-9 (Pubitemid 351945567)
96. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005;129:512-21 (Pubitemid 41096639)
97. Tarantino G, Conca P, Basile V, et al. A prospective study of acute drug-induced liver injury in patients suffering from non-Alcoholic fatty liver disease. Hepatol Res 2007;37:410-15 (Pubitemid 46915785)
98. Labarga P, Soriano V, Vispo ME, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007;196:670-6 (Pubitemid 47293847)
99. Day CP. Nash-related liver failure: one hit too many? Gastroenterology 2002;97:1872-4
100. Khorashadi S, Hasson NK, Cheung RC. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol 2006;4:902-7 (Pubitemid 43994535)
101. Lewis JH, Mortenson ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007;46:1453-63 (Pubitemid 350155527)
102. Ekstedt M, Franzen LE, Mathiesen UL, et al. Statins in non-Alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007;47:135-41 (Pubitemid 46817693)
103. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000;22:685-708 (Pubitemid 30451995)
104. Kramer JR, Giordano TP, Souchek J, et al. Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. J Hepatol 2005;42:309-14 (Pubitemid 40254243)
105. Aceti A, Pasquazzi C, Zechini B, et al. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: The role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002;29:41-8 (Pubitemid 34094305)
106. Aranzabal L, Casado JL, Moya J, et al. Influence of liver fibrosis on highly active antiretroviral therapy-Associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2005;40:588-93 (Pubitemid 40270230)
107. Ito H, Yoshioka K, Ukai K, et al. The fluctuations of viral load and serum alanine aminotransferase levels in chronic hepatitis C. Hepatol Res 2004;30:11-17 (Pubitemid 39145034)
108. Galan MV, Potts J A, Silverman AL, et al. The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center. J Clin Gastroenterol 2005;39:64-7 (Pubitemid 40041347)
109. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007
110. Tolman KG. The liver and lovastatin. Am J Cardiol 2002;89:1374-80 (Pubitemid 34607777)
111. Bader T. The myth of statin-induced hepatotoxicity. Am J Gastroenterol 2010;105:978-80
112. Bjornsson E, Jacobsen E, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol 2012;56:49-9
113. Tolman K. The liver and lovastatin. ACC Curr J Rev 2002;11:1374-80 (Pubitemid 34607777)
114. Bader T. Editorial: Yes Statins can be given to liver patients. J Hepatol 2012;56:305-7
115. Bessone F. Non-steroidal anti-inflammatory drugs: what is the actual risk of liver damage? World J. Gastroenterol 2010;16:5651-61
116. Walker AM. Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal anti-inflammatory drugs. Arthritis Rheum 1997;40:201-8 (Pubitemid 27114083)
117. Bjorkman D. Nonsteroidal anti-inflammatory drug-Associated toxicity of the liver, lower gastrointestinal tract, and esophagus. Am J Med 1998;105:17S-21S (Pubitemid 28553711)
118. Chitturi S, Farrell GC. Lessons from lumiracoxib: are cyclooxygenase-2 inhibitors less hepatotoxic than non-selective nonsteroidal anti-inflammatory drugs? J Gastroenterol Hepatol 2012;27:993-4
119. El Hajj II, Malik SM, Alwakeel HR, et al. Celecoxib-induced cholestatic liver failure requiring orthotopic liver transplantation. World J Gastroenterol 2009;15:3937-9
120. Papachristou GI, Demetris AJ, Rabinovitz M. Acute cholestatic hepatitis associated with long-Term use of rofecoxib. Dig Dis Sci 2004;49:459-61 (Pubitemid 38453565)
121. Laine L, White WB, Rostom A, Hochberg M. COX-2 selective inhibitors in the treatment of osteoarthritis. Semin Arthritis Rheum 2008;38:165-87
122. Lee CH, Wang JD, Chen PC. Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs. Pharmacoepidemiol Drug Saff 2010;19:708-14
123. Gulmez SE, Larry D, Pageaux GE, et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (Acetaminophen). The Multinational Case-Population SALT Study. Drug Saff 2013;36:135-44
124. MRHA. Lumiracoxib: suspension of Marketing Authorisations. Drug Saf Update 2007;1:15
125. Efe C. Drug induced autoimmune hepatitis and TNF-Alpha blocking agents: is there a real relationship? Autoimmun Rev 2013;12:337-9
126. Tobon GJ, Canas C, Jaller JJ, et al. Serious liver disease induced by infliximab. Clin Rheumatol 2007;26:578-81 (Pubitemid 46359303)
127. Garc?a Aparicio AM, Rey JR, Sanz AH, et al. Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab. Clin Rheumatol 2007;26:811-13 (Pubitemid 46554102)
128. Ojiro K, Naganuma M, Ebinuma H, et al. Reactivation of hepatitis B in a patient with Crohns disease treated using infliximab. J Gastroenterol 2008;43:397-401 (Pubitemid 351958904)
129. Germano V, Picchianti Diamanti A, et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005;64:1519-20 (Pubitemid 41623873)
130. Marques M, Magro F, Cardoso H, et al. Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis. Inflamm Bowel Dis 2008;14:723-5 (Pubitemid 351743000)
131. Harada K, Akai Y, Koyama S, et al. A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis. Clin Rheumatol 2008;27:1063-6
132. Takeuchi T, Tatsuki Y, Nogami Y, et al. Post marketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:189-94 (Pubitemid 351183307)
133. Seeff LB. Herbal hepatotoxicity. Clin Liver Dis 2007;11:577-96 (Pubitemid 47302344)
134. Elinav E, Pinsker G, Safadi R, et al. Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity. J Hepatol 2007;47:514-20 (Pubitemid 47331750)
135. Schoepfer AM, Engel A, Fattinger K, et al. Herbal does not mean innocuous: Ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products. J Hepatol 2007;47:521-6 (Pubitemid 47331751)
136. Sarma DN, Barrett ML, Chavez ML, et al. Safety of green tea extracts: a systematic review by the US Pharmacopeia. Drug Saf 2008;31:469-84 (Pubitemid 351693681)
137. Javaid A, Bonkovsky HL. Hepatotoxicity due to extracts of Chinese green tea (Camellia sinensis): a growing concern. J Hepatol 2006;45:334-6
138. Teschke R, Frenzel C, Glass X, et al. Herbal hepatotoxicity: a critical review. Br J Clin Pharmacol 2013;75:630-6
139. Graham DJ, Green L, Senior JR, et al. Troglitazone-induced liver failure: a case study. Am J Med 2003;114:299-306 (Pubitemid 36398076)
140. DP Bartell. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;2:281-7
141. Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 2009;106:4402-7
142. Starkey Lewis PJ, Dear J, et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 2011;54:1767-76
143. Laverty HG, Antoine DJ, Benson C, et al. The potential of cytokines as safety biomarkers for drug-induced liver injury. Eur J Clin Pharmacol 2010;66:961-76